Obesity and type 2 diabetes damage bone differently, linked to changes in antimicrobial peptide CRAMP
In mice, obesity reduced bone thickness while insulinopenic type 2 diabetes decreased trabecular number and bone stiffness, with diabetes-related bone damage correlating with reduced circulating levels of the antimicrobial peptide CRAMP.
Quick Facts
What This Study Found
Hyperinsulinemic obesity decreased trabecular and cortical bone thickness with BMAT expansion but preserved CRAMP levels. Insulinopenic T2D decreased trabecular number, impaired bone stiffness, and reduced circulating CRAMP peptide levels, suggesting a link between insulin deficiency, bone quality, and innate immune peptide regulation.
Key Numbers
C57BL/6J male mice on high-fat diet (16 weeks) for obesity model. Streptozotocin + HFD for insulinopenic T2D model. Compared to low-fat diet controls. Assessed bone phenotype and bone marrow adipose tissue.
How They Did This
Controlled animal study using C57BL/6J male mice with high-fat diet (HFD) for obesity and HFD + streptozotocin (STZ) for insulinopenic T2D, assessed over 8-16 weeks via micro-CT bone analysis, biomechanical testing, BMAT quantification, and serum CRAMP measurement.
Why This Research Matters
Both obesity and diabetes increase fracture risk, but through different mechanisms. Understanding that the antimicrobial peptide CRAMP is specifically reduced in insulinopenic diabetes—not obesity—could reveal new biomarkers for diabetes-related bone fragility and potential therapeutic targets at the intersection of innate immunity and bone health.
The Bigger Picture
This study connects two growing research areas—peptide-based innate immunity and metabolic bone disease. The finding that CRAMP (the mouse equivalent of human LL-37) is specifically downregulated in diabetic bone disease opens questions about whether antimicrobial peptides serve dual roles in immune defense and metabolic bone health.
What This Study Doesn't Tell Us
Mouse model only—STZ-induced diabetes does not perfectly replicate human T2D pathophysiology. Only male mice studied. Correlation between CRAMP reduction and bone changes does not establish causation. Human cathelicidin (LL-37) may behave differently than mouse CRAMP.
Questions This Raises
- ?Could restoring CRAMP/LL-37 levels protect bone quality in diabetic patients?
- ?Is circulating LL-37 reduced in human type 2 diabetes and does it correlate with fracture risk?
- ?What molecular pathway connects insulin deficiency to CRAMP peptide downregulation?
Trust & Context
- Key Stat:
- CRAMP drops in diabetes, not obesity Circulating antimicrobial peptide CRAMP decreased specifically in insulinopenic diabetic mice with impaired bone quality, not in obese mice
- Evidence Grade:
- Well-controlled preclinical study with appropriate disease models and comprehensive bone analysis. Novel finding linking CRAMP to diabetic bone disease, but mechanistic pathways and human relevance need confirmation.
- Study Age:
- Published in 2025; represents emerging research on antimicrobial peptides in metabolic bone disease.
- Original Title:
- Obesity and insulinopenic type 2 diabetes differentially impact, bone phenotype, bone marrow adipose tissue, and serum levels of the cathelicidin-related antimicrobial peptide in mice.
- Published In:
- Bone, 193, 117387 (2025)
- Authors:
- Paquet, Amélie, Bahlouli, Nadia, Coutel, Xavier, Leterme, Damien, Delattre, Jérôme, Gauthier, Véronique, Miellot, Flore, Delplace, Séverine, Rouge-Labriet, Hélène, Bertheaume, Nicolas, Chauveau, Christophe, Benachour, Hamanou
- Database ID:
- RPEP-12952
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is CRAMP and why is it relevant to bone health?
CRAMP (cathelicidin-related antimicrobial peptide) is the mouse equivalent of human LL-37, part of the innate immune system. This study discovered that CRAMP levels drop specifically in insulinopenic diabetes alongside bone deterioration, suggesting antimicrobial peptides may play a previously unrecognized role in metabolic bone health.
Does obesity or diabetes cause worse bone damage?
They cause different types of damage. Obesity reduced bone thickness and expanded bone marrow fat, while insulinopenic diabetes reduced the number of trabecular bone structures and impaired overall bone stiffness. The diabetes-related changes may be more functionally significant for fracture risk.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12952APA
Paquet, Amélie; Bahlouli, Nadia; Coutel, Xavier; Leterme, Damien; Delattre, Jérôme; Gauthier, Véronique; Miellot, Flore; Delplace, Séverine; Rouge-Labriet, Hélène; Bertheaume, Nicolas; Chauveau, Christophe; Benachour, Hamanou. (2025). Obesity and insulinopenic type 2 diabetes differentially impact, bone phenotype, bone marrow adipose tissue, and serum levels of the cathelicidin-related antimicrobial peptide in mice.. Bone, 193, 117387. https://doi.org/10.1016/j.bone.2024.117387
MLA
Paquet, Amélie, et al. "Obesity and insulinopenic type 2 diabetes differentially impact, bone phenotype, bone marrow adipose tissue, and serum levels of the cathelicidin-related antimicrobial peptide in mice.." Bone, 2025. https://doi.org/10.1016/j.bone.2024.117387
RethinkPeptides
RethinkPeptides Research Database. "Obesity and insulinopenic type 2 diabetes differentially imp..." RPEP-12952. Retrieved from https://rethinkpeptides.com/research/paquet-2025-obesity-and-insulinopenic-type
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.